|
Kantargian reported on a study using
decitabine
to treat chronic myelogenous leukemia in a total of 81 patients with a
response rate of 62 percent among patients in chronic phase of the disease.
First, Kantargian reported on three studies of decitabine to treat
myelodysplastic syndrome (MDS) in 125 total patients with an overall
response
rate of 49 percent. Also, Kantargian reported on a study using
decitabine
to treat chronic myelogenous leukemia (CML) in a total of 81 patients with a
response rate of 62 percent among patients in chronic phase of the disease.
Previously, SuperGen announced that decitabine generated a response in
100
percent of the patients tested in a Phase I/II clinical study designed to
establish safety and efficacy in the treatment of sickle cell anemia. These
data were published in the October issue of Blood.
"These studies continue to give us great hope that decitabine is a
platform technology for the treatment of cancer," said Dr. Joseph Rubinfeld,
chairman and chief executive officer of SuperGen. "Our compound's unique
mechanism of action — the hypomethylation of DNA — is a ground-breaking area
of
significant interest in the reactivation of tumor suppressor genes in cancer
therapy. These exciting data associated with decitabine underscore the
breadth
of the SuperGen drug-portfolio, which includes four compounds that will be
in
Phase III clinical trials soon."
Based in San Ramon, Calif., SuperGen is a pharmaceutical company
dedicated to the development and commercialization of products intended to
treat life-threatening diseases, particularly cancer.
Source: SuperGen Inc.
CMLSupport Home Page This site was last updated on Nov. 18, 2000 Copyright © 2000 CMLSupport.com These contents may not be reproduced in whole or in part without the express written permission of the author, or she will beat you up and stuff. |